The role of Gliadel wafers in the treatment of high-grade gliomas

References

• Affronti ML, Heery CR, Herndon JE 2nd et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115, 3501–3511 (2009).
   PubMed Web of Science ®Google Scholar
• Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther. Clin. Risk Manag. 3, 707–715 (2007).
   PubMedGoogle Scholar
• Buonerba C, Di Lorenzo G, Marinelli A et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit. Rev. Oncol. Hematol. 80, 54–68 (2011).
   PubMed Web of Science ®Google Scholar
• Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J. Neurooncol. 72, 241–244 (2005).
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann.Surg. Oncol. 15, 2887–2893 (2008).
   PubMed Web of Science ®Google Scholar
• Mangiola A, de Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113(4), 841–846 (2008).
   PubMed Web of Science ®Google Scholar
• Mangiola A, Saulnier N, De Bonis P et al. Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PloS ONE 8(3), e57145 (2013).
   PubMed Web of Science ®Google Scholar
• Prager JM, Grenier Y, Cozzens JW, Chiowanich P, Gorey MT, Meyer JR. Serial CT and MR imaging of carmustine wafers. AJNR Am. J. Neuroradiol. 21(1), 119–123 (2000).
   Google Scholar
• Dyke JP, Sanelli PC, Voss HU et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J. Neurooncol. 82, 103–110 (2007).
   PubMed Web of Science ®Google Scholar
• Balossier A, Dörner L, Emery E et al. Incorporating BCNU wafers into malignant glioma treatment: European case studies. Clin. Drug Investig. 30, 195–204 (2010).
   Google Scholar
• Panigrahi M, Das PK, Parikh PM. Brain tumor and Gliadel wafer treatment. Indian J. Cancer 48(1), 11–7 (2011).
   PubMed Web of Science ®Google Scholar
• McGovern PC, Lautenbach E, Brennanl PJ, Lustig RA, Fishman NO. 0 Risk Factors for Postcraniotomy Surgical Site Infection after 1, 3-Bis (2-Chloroethyl) - 1-Nitrosourea (Gliadel) Wafer Placement. Clin. Infect. Dis. 2699, 759–765 (2003).
   Google Scholar
• Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta neurochir. 149, 261–265, discussion 265 (2007).
   PubMed Web of Science ®Google Scholar
• Giese A, Kucinski T, Knopp U et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J. Neurooncol. 66(3), 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Miglierini P, Bouchekoua M, Rousseau B, Hieu PD, Malhaire JP, Pradier O. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin. Neurol. Neurosurg. 114(9), 1222–1225 (2012).
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta neurochir. 148, 269–275, discussion 275 (2006).
   PubMed Web of Science ®Google Scholar
• Menei P, Metellus P, Parot-Schinkel E et al.; Neuro-oncology Club of the French Society of Neurosurgery. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann. Surg. Oncol. 17, 1740–1746 (2010).
   PubMed Web of Science ®Google Scholar
• Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg. Neurol. 53(5), 458–464 (2000).
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1), 44–48, discussion 48–49 (1997).
   PubMed Web of Science ®Google Scholar
• Noël G, Schott R, Froelich S et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 749–755 (2012).
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg. 110, 583–588 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat. Rev. 9(4), 313–330 (1982).
   Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial Chemotherapy of the 9L Gliosarcoma: Controlled Release Polymers for Drug Delivery in the Brain. Cancer Res. 53(2), 329–333 (1993).
   PubMed Web of Science ®Google Scholar
• Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother. Pharmacol. 65, 137–142 (2009).
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 79(3–4), 141–152 (2006).
   Google Scholar
• De Bonis P, Anile C, Pompucci A. et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir. (Wien), 154(8), 1371–1378 (2012).
   Google Scholar
• Lechapt-Zalcman E, Levallet G, Dugué AE et al. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118(18), 4545–4554(2012).
   PubMed Web of Science ®Google Scholar
• Ulmer S, Spalek K, Nabavi A et al. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro. Oncol. 14(4), 482–490(2012).
   Google Scholar
• Chaichana KL, Zaidi H, Pendleton C et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol. Res. 33(7), 759–764 (2011).
   PubMed Web of Science ®Google Scholar
• Della Puppa A, Rossetto M, Ciccarino P et al. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series. World Neurosurg. 76(1–2), 156–159; discussion 67-8 (2011).
   Google Scholar
• Salmaggi A, Milanesi I, Silvani A et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J. Neurosurg. 118(4), 821–829 (2013).
   PubMed Web of Science ®Google Scholar
• Duntze J, Litré CF, Eap C et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann. Surg. Oncol. 20(6), 2065–2072 (2013).
   PubMed Web of Science ®Google Scholar
• Smith KA, Ashby LS, Gonzalez LF et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J. Neurosurg. 109(Suppl.)106–117 (2008).
   PubMedGoogle Scholar
• Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro. Oncol. 7(1), 84–89 (2005).
   PubMed Web of Science ®Google Scholar
• Kleinberg LR, Weingart J, Burger P et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest. 22(1), 1–9 (2004).
   PubMed Web of Science ®Google Scholar